Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 5/20 | 0.49 |
| ▸ | TERT | O14746 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | PPARD | Q03181 | 3/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | FABP4 | P15090 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5066137 | 1.00 | PRKCA (0.49) | PRKCAFAAHTERTPTPN1PPARG | |
| SCHEMBL17780094 | 1.00 | PRKCA (0.49) | PRKCAFAAHTERTPTPN1PPARG | |
| SCHEMBL5066142 | 1.00 | PRKCA (0.49) | PRKCAFAAHTERTPTPN1PPARG | |
| SCHEMBL2779350 | 1.00 | PRKCA (0.49) | PRKCAFAAHTERTPTPN1PPARG | |
| SCHEMBL18206407 | 1.00 | PRKCA (0.49) | PRKCAFAAHTERTPTPN1PPARG | |
| SCHEMBL12435787 | 0.96 | MGLL (0.55) | FAAHPPARGPPARDPPARAHSD17B10 | |
| SCHEMBL23417025 | 0.92 | FAAH (0.56) | FAAHPPARGPPARDPPARAMAPT | |
| SCHEMBL27409126 | 0.91 | MGLL (0.43) | PRKCAFAAHMAPTKMT2APGR | |
| SCHEMBL1361856 | 0.91 | KMT2A (0.54) | PRKCAKMT2ALMNA | |
| SCHEMBL18218758 | 0.91 | KMT2A (0.54) | PRKCAKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110064652-A1 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS TO THE LUNG | BORLAK JUERGEN | 2011-03-17 | — | — | US | claimed |
| EP-2257312-A2 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS TO THE LUNG | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2010-12-08 | — | — | EP | claimed |
| WO-2009121631-A2 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS TO THE LUNG | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2009-10-08 | — | — | WO | claimed |
| EP-2106806-A1 | Nanoparticles for targeted delivery of active agents to the lung | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. (DE) | 2009-10-07 | — | — | EP | claimed |
| EP-1996234-A2 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-12-03 | — | — | EP | claimed |
| US-20080267876-A1 | Nanoparticles for Targeted Delivery of Active Agent | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2008-10-30 | — | — | US | claimed |
| WO-2007034479-A2 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2007-03-29 | — | — | WO | claimed |
| EP-4734929-A1 | SYSTEM AND METHODS FOR MODIFYING SURFACE PROPERTIES OF KERATIN-CONTAINING SURFACES | Edulis Labs Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250325491-A1 | POLYVALENT MOLECULE BASED LIPID NANOPARTICLES FOR NUCLEIC ACID DELIVERY | BIO TRIP B V (NL) | 2025-10-23 | — | — | US | disclosed |
| CN-119522092-A | Multivalent molecule-based lipid nanoparticles for nucleic acid delivery | 比奥-特里普公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2025006080-A1 | SYSTEM AND METHODS FOR MODIFYING SURFACE PROPERTIES OF KERATIN-CONTAINING SURFACES | EDULIS LABS INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-0833613-A1 | DELIVERY VEHICLES COMPRISING STABLE LIPID/NUCLEIC ACID COMPLEXES | SOMATIX THERAPY CORPORATION (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996037194-A1 | DELIVERY VEHICLES COMPRISING STABLE LIPID/NUCLEIC ACID COMPLEXES | SOMATIX THERAPY CORPORATION (US) | 1996-11-28 | — | — | WO | disclosed |
| US-5153173-A | Administering to humans and animals to modulate immunoresponse | PLIVA FARMACEUTSKA (YU) | 1992-10-06 | — | — | US | disclosed |
| EP-0390039-A2 | N-Acyl derivatives of the peptidoglycan monomer, pharmaceutically acceptable salts thereof, their preparation and use in the manufacture of immunomodulators and immunoadjuvants | PLIVA FARMACEUTSKA, KEMIJSKA, PREHRAMBENA I KOZMETICKA INDUSTRIJA S P.O. (YU) | 1990-10-03 | — | — | EP | disclosed |
| EP-0094804-B1 | GLUCOSAMINYL MURAMYL PEPTIDE DERIVATIVES | Dainippon Pharmaceutical Co., Ltd. (JP) | 1985-11-13 | — | — | EP | disclosed |
| US-4545932-A | NONSPECIFIC RESISTANCE TO MICROBIAL INFECTIONS, IMMUNOSTIMULANTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1985-10-08 | — | — | US | disclosed |
| EP-0094804-A1 | Glucosaminyl muramyl peptide derivatives | Dainippon Pharmaceutical Co., Ltd. (JP) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | SOD1, SOD3, SMN1; SMN2 | PRKCA 4584/4885FAAH 4133/4885TERT 1601/4885 |
| US-20250325491-A1 | POLYVALENT MOLECULE BASED LIPID NANOPARTICLES FOR NUCLEIC ACID DELIVERY | POLRMT, TLR3, TLR9 | PRKCA 1052/4885FAAH 3727/4885TERT 1734/4885 |
| US-20110064652-A1 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS TO THE LUNG | MLEC, ALK, ICMT | PRKCA 2210/4885FAAH 3527/4885TERT 1239/4885 |
| US-20080267876-A1 | Nanoparticles for Targeted Delivery of Active Agent | MLEC, OGA, ILK | PRKCA 3090/4885FAAH 2745/4885TERT 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.